Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...

An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of miracle and wonder." The post “What I Wish I’d Known About Cataract ...

Growing at a rapid pace, Apex Eyecare is poised to hire a second optometrist and a nurse practitioner in the coming months, ...

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; ...

Since Roche launched its long-acting eye disease medicine Vabysmo in 2022, Bayer and Regeneron have seen the impact on sales of their rival treatment Eylea, with the U.S. biotech taking a bigger hit.

Rare neuromuscular diseases often lack treatments because developing targeted drugs is slow, costly and risky for companies.

In an observational claims database, patients using GLP-1 receptor agonists (GLP-1RAs) had significantly lower risk of ...

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved ...